Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sjögren's
syndrome (SS) are heterogeneous autoimmune diseases. Severe manifestations and …

The steadily increasing knowledge regarding pathogenetic mechanisms in autoimmune
rheumatic diseases has paved the way to different therapeutic approaches. In particular, the …

This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …

For nearly three decades, chimeric antigen receptors (CARs) have captivated the interest of
researchers seeking to find novel immunotherapies to treat cancer. CARs were first …

Objectives To analyse the current evidence for the management of lupus nephritis (LN)
informing the 2019 update of the EULAR/European Renal Association-European Dialysis …

Background Long-term treatment programs with low toxicity represent a therapeutic
challenge in lupus nephritis (LN). Although a therapeutic benefit of rituximab (RTX) has …

Systemic lupus erythematosus (SLE) is a serious autoimmune disease with variety of organ
manifestations. The most dreadful one, affecting the majority of SLE patients, is kidney …

Chimeric antigen receptor (CAR) T cell therapy has become an important treatment for
hematological cancers, and its success has spurred research into CAR T cell therapies for …

Objective Rituximab (RTX) has important usage in rheumatoid arthritis and vasculitis. There
remains a need for more, better, and safer treatments for patients with lupus nephritis (LN) …